Presentation of bladder leiomyoma concurrent with transitional cell carcinoma

We report a case of a 46-year-old male who presented to the outpatient urology clinic with an incidental bladder mass. Office cystoscopy revealed two synchronous tumors of different morphology. Endoscopic resection was performed to remove the smaller, papillary tumor, of which pathology revealed Ta, Grade 1 urothelial carcinoma. A second open resection was performed to remove the second tumor, a benign leiomyoma.     

Simultaneous renal cell carcinoma of the kidney and transitional cell carcinoma of the bladder

Herein we report a rare combination of two urological tumors simultaneously: renal cell carcinoma of the kidney and transitional cell carcinoma of the bladder. A 67 year old male presented with hematuria. He was diagnosed with left renal cell carcinoma and transitional cell carcinoma of the bladder. Subsequently this patient underwent left nephrectomy (palliative) to control the pain and transurethral resection of bladder tumor. The clinical picture, radiographic and histological finding are presented, as well as the treatment offered.     

膀胱移行上皮细胞癌中穿通支原体的检出及意义

目的探讨穿通支原体(Mycoplasma penetrans,Mpe)在膀胱移行上皮细胞癌患者血液和肿瘤组织中的分离检出及意义。方法将55例膀胱移行上皮细胞癌患者的膀胱组织标本、血液标本分别接种于改良SP-4液体培养基中进行支原体分离培养,可疑阳性菌株用PCR予以证实。结果55例患者的Mpe累计分离率为41.8%(23/55),对照组的分离率为11.1%(3/27),两组比较有统计学意义(P<0.05)。将患者按UICC-TNM标准进行分期,浸润癌(T2~T4)组Mpe分离率为69.0%(9/13),非浸润癌(Ta~T1)组为33.0%(14/42),两组比较差异也有统计学意义(P<0.05)。结论膀胱移行上皮细胞癌患者的膀胱组织、血液中Mpe分离阳性率高,且浸润性膀胱癌组较非浸润癌组高,提示Mpe感染与膀胱移行上皮细胞癌的发生有一定关联,与肿瘤是否浸润也存在一定关系。     

Metastatic umbilical mass from transitional cell carcinoma of the bladder

We present the case of an 83-year-old female presenting with an umbilical mass measuring 2 cm x 3 cm. This patient had an extensive prior history of transitional cell carcinoma of the bladder. A fine needle aspiration of this umbilical mass confirmed this to be metastatic transitional cell carcinoma and the diagnostic workup demonstrated the presence of invasive bladder cancer with metastatic liver lesions.     

Gemcitabine-induced vasculitis in advanced transitional cell carcinoma of the bladder

Background Gemcitabine (GEM) is an alternative chemotherapeutic agent for patients with metastatic bladder cancer. It is believed to be a well-balanced agent, having acceptable toxicity and enhanced antitumor activity. The integration of GEM into the initial chemotherapy plan for these patients is still being developed.Case report The patient, male, aged 56 years, was suffering from a transitional cell carcinoma of the bladder. Due to frequent local superficial recurrences, radical cystectomy with pelvic lymphadenectomy and continent ileal diversion was performed. Four years after the operation a left inguinal lymphadenopathy was noted and metastatic bladder carcinoma was confirmed on biopsy. Cytotoxic therapy combining GEM and cisplatin and local external irradiation therapy was initiated. The patient developed extensive necrotising vasculitis with muscle damage after the second course of therapy. Chemotherapy was stopped immediately but this was not enough to relieve the symptoms of severe myalgia and swelling, and additional treatment consisting of cyclophosphamide and prednisolone was initiated.Conclusion Although GEM seems to be relatively safe, some unexpected complications may occur during treatment. This case is not common, but it reinforces the need for careful attention to any new symptoms that seem to be unassociated with the primary disease. Prompt evaluation of such symptoms should be carried out in patients receiving GEM therapy.     

Correlation between human papillomavirus infection and bladder transitional cell carcinoma

Background  

To determine the association of human papillomavirus infection (HPV) and transitional cell carcinoma (TCC).     

尿BTA测定对膀胱肿瘤的早期诊断价值

对 47例膀胱移行细胞癌 (BTCC组 )、2 8例膀胱良性肿瘤 (良性组 )及 2 5例健康志愿者 (对照组 )行尿膀胱肿瘤抗原 (BTA)测定及尿脱落细胞学 (VUC)检查。结果 :BTCC组与对照组、良性组的尿 BTA浓度分别为(4.83± 1.81) U/ m l、(1.19± 0 .2 1) U/ ml、(1.3 7± 0 .68) U/ ml。BTCC组尿 BTA浓度与良性组及对照组比较均存在显著差异 (P<0 .0 1)。尿 BTA测定对 BTCC的诊断有较高的敏感性 (85 .1% )和特异性 (88.9% ) ,优于 VU C检查。 BTA浓度与膀胱肿瘤的临床分期和病理分级呈正相关。 BTA与 VUC同时应用可提高 BTCC检出率。认为BTA测定可提高 BTCC早期诊断率、对其治疗和随访均有指导意义     

Adjuvant chemotherapy in colorectal carcinoma

Despite the National Institutes of Health consensus regarding use of adjuvant chemotherapy in colorectal carcinoma, many general surgeons question the efficacy of this approach when considering costs involved for both the individual patient and society at large. PURPOSE: This study was designed to determine the real impact of adjuvant chemotherapy on five-year survival rates of patients. METHOD: A qualitative and quantitative meta-analysis of results from 39 randomized clinical trials published from 1959 to 1993 is described. RESULTS: Design quality of clinical trials had a mean score of 48.6 percent (±6.2 standard deviation). A small benefit of therapy in terms of overall survival was noted, with a mortality odds ratio (OR) of 0.91 (confidence interval (CI) 95 percent, 0.83–0.99). For the group of colon carcinomas, the OR was 0.81 (CI 95 percent, 0.69–0.94) with an OR of 0.64 (CI 95 percent, 0.48–0.85) for the group of rectal carcinomas. The effect size was 0.09 for the colon group and 0.20 for the rectal group. For those patients who receive chemotherapy, this effect size implies that we can expect an increase of 5 percent in the survival rate in the group with colon carcinoma and a 9 percent increase in the survival rate in the group with rectal carcinoma. CONCLUSION: Given the high incidence of colorectal carcinoma, the small benefit observed for those patients receiving chemotherapy is far from negligible. However, indications for adjuvant chemotherapy warrant further discussion.Read at the meeting of The American Society of Colon and Rectal Surgeons, Montreal, Quebec, Canada, May 7 to 12, 1995.     

Synchronous transitional cell carcinoma and metastatic hepatocellular carcinoma in the urinary bladder: a case report

An 83- year-old male presented with intermittent hematuria and obstructive symptoms. A CT scan of the abdomen and pelvis showed diffuse thickening of the urinary bladder and a large 10 cm liver mass. Histopathological examination of bladder biopsy demonstrated two distinct lesions. The surface showed non-invasive urothelial carcinoma and the submucosa demonstrated metastatic hepatocellular carcinoma showing bile pigment and expressed Hep Par 1 and CD10. To the best of our knowledge, this is the first case report of synchronous transitional cell carcinoma and metastatic hepatocellular carcinoma of the urinary bladder.     

膀胱癌组织中趋化因子受体CXCR7的表达变化及意义

目的观察膀胱癌组织中趋化因子受体CXCR7的表达变化及意义。方法收集37例膀胱癌患者的癌组织（观察组）和29例癌旁正常组织（对照组）,采用逆转录聚合酶链反应法（RT—PCR）和免疫组化法分别检测其中的CXCR7 mRNA和蛋白。结果观察组CXCR7 mRNA相对表达量为0．692±0．071,明显高于对照组的0．432±0．148,P〈0．05。观察组中浅表性膀胱癌CXCR7 mRNA相对表达量为0．676±0．065,明显低于浸润性膀胱癌组织中的0．731±0．074,但二者均高于对照组,P均〈0．05。观察组11例CXCR7蛋白低表达、26例高表达,对照组分别为23、6例,两组CXCR7蛋白表达情况相比P〈0．05。观察组26例浅表性膀胱癌中15例CXCR7高表达,11例浸润性膀胱癌CXCR7均为高表达。CXCR7表达情况与膀胱癌临床分期有关（P〈0．05）。CXCR7表达情况与膀胱癌患者年龄、性别无关（P均〉0．05）。结论膀胱癌组织中CXCR7 mRNA和蛋白表达升高。检测膀胱癌组织中的CXCR7 mRNA或蛋白可能有助于判断膀胱癌的临床分期。     

TERT在膀胱移行细胞癌中的表达及临床意义

为了研究端粒酶逆转录酶 (TERT)在膀胱移行细胞癌 (TCC)中的表达特征 ,探讨 TERT与 TCC生物学行为的关系 ,选取不同分期、分级的膀胱移行细胞癌组织、癌旁组织、正常膀胱组织 ,用 TERT抗体和链酶卵蛋白 -过氧化物酶 (SP)免疫组织化学方法染色 ,观察 TERT的表达程度。结果显示 :TERT阳性的细胞主要是肿瘤细胞 ,免疫组化染色阳性表现为肿瘤细胞浆及部分胞核的棕黄色颗粒。TCC组织 TERT阳性率为 81.9% ,不同病理分级、临床分期之间无显著性差异 (P>0 .0 5 )。认为 TCC组织中 TERT阳性率明显高于正常膀胱粘膜组织及癌旁粘膜组织 ,TERT可作为 TCC早期诊断、鉴别诊断及预测复发的肿瘤标志物之一。     

Adjuvant chemotherapy after liver transplantation for hepatocellular carcinoma

<正>In this issue,Lin et al~([1])presented a well-written metaanalysis regarding the use of adjuvant chemotherapy in orthotopic liver transplant(OLT)recipients with hepatocellular carcinoma(HCC).They highlighted the need for further investigation about the post-OLT management of HCC.The treatment of advanced HCC remains a difficult challenge as there is limited     

Palliative chemoirradiation for transitional carcinoma of the bladder: a case report

Palliation of locally advanced transitional carcinoma of the bladder is a major problem that has not been well investigated. Recent reports from the curative literature suggest improved tumor response rates using platinum based chemoirradiation over radiotherapy alone. Because of the poor symptomatic responses seen with conventional palliative radiotherapy, we have been treating selected cases of locally advanced bladder carcinoma palliatively with low dose chemoirradiation. We present a case of an elderly female treated this way with an excellent clinical response.     

Metastasis from transitional cell carcinoma of urinary bladder as cystic pulmonary lesion

Pulmonary metastases from transitional cell carcinoma usually present as multiple nodules, solitary mass, or interstitial micronodules but rarely manifested as cystic pulmonary lesions. We report an atypical case of multiple cavitating pulmonary metastases from transitional cell carcinoma of urinary bladder. Infectious disease is ruled out by sputum examination, laboratory exams and failure of response to antibiotic therapy. In closure, the need to exclude a second primary tumor led us to perform a fine-needle aspiration biopsy by which metastatic transitional cell carcinoma was diagnosed. Inadequacy of blood supply with necrosis may be advocated as possible mechanism of cavitations of the lesion.